Experimentellt mRNA-vaccin visar skydd mot flera ebolavirus

22 maj 2026

Rapporterad av AI

Ett experimentellt mRNA-vaccin har uppvisat effektivitet mot tre stammar av ebolavirus i tester på gnagare. Vaccinet riktar sig mot Zaire-, Sudan- och Bundibugyo-virus. Forskare utvecklade vaccinet under ett pågående utbrott av Bundibugyo-virus i Afrika.

Yanfeng Yao och kollegor vid Wuhan Institute of Virology skapade vaccinet genom att kombinera mRNA-sekvenser för glykoproteiner från varje virus tillsammans med ett gemensamt nukleoprotein inuti en lipidnanopartikel. I tester uppnådde vaccinerade möss ett fullständigt skydd mot Zaire- och Sudan-virus samt ett starkt skydd mot Bundibugyo. Hamstrar erhöll även fullt skydd mot exponering för Sudan-virus.

Relaterade artiklar

A volunteer receiving a needle-free vaccine in a lab with AI-designed virus models in the background.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

5 juni 2026 Rapporterad av AI Bild genererad av AI Faktagranskad

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Engineered phages redirect vaccine immunity to eradicate tumors in mice

Researchers have used genetically modified phages to harness pre-existing vaccine immunity and destroy cancer cells in mice. The approach eradicated tumors in 44 percent of treated animals with no recurrence after a year.

Moderna advances hantavirus vaccine after cruise ship deaths

11 maj 2026 Rapporterad av AI

Moderna confirmed ongoing work on an mRNA vaccine for hantavirus following a deadly outbreak on a Dutch cruise ship. The effort, in partnership with Korea University, began in 2023 and shows promise but remains years from completion.

Asia

Philippines remains free of Ebola, DOH says

Africa

Scientists warn of bat coronavirus risk in East Africa

Africa

WHO warns of Ebola spread risk as Kenya activates emergency response measures

Virus injection halts pancreatic tumor growth in trial

A genetically engineered virus has stopped pancreatic tumors from growing in three patients in an early US clinical trial. The results come from a safety study led by researchers at the University of Minnesota.

Scripps researchers reveal HIV and Ebola weak spots using nanodiscs

12 april 2026 Rapporterad av AI

Scientists at Scripps Research have developed a nanodisc platform that mimics viral membranes, uncovering hidden interactions in HIV and Ebola proteins that traditional methods miss. The technology allows for more accurate study of antibody responses, potentially accelerating vaccine development. The findings appear in Nature Communications.

13 juni 2026 13:47